BioCentury
ARTICLE | Clinical News

Gazyvaro regulatory update

August 4, 2014 7:00 AM UTC

The European Commission approved Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line treatment of chronic lymphocytic leukemia (CLL) in patients unsuitable for fludarabine-...